Apatinib is a medication used to treat various types of cancer, including gastric cancer, liver cancer, and non-small cell lung cancer. It is a tyrosine kinase inhibitor that works by blocking the signals that promote tumor growth and angiogenesis (the formation of new blood vessels that supply nutrients to tumors). Apatinib is also known by various synonyms, such as Rivoceranib and YN968D1. In this article, we will discuss the chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion of Apatinib.
Chemical name:
The IUPAC name of Apatinib is 4-[2-(4-{3-[(dimethylamino)methyl]phenyl}piperazin-1-yl)-2-oxoethyl]-N,N-dimethyl-2-(4-pyridinyl)-2H-pyrimidine-6-carboxamide.
Molecular formula:
The molecular formula of Apatinib is C24H23N7O4.
Formula weight:
The formula weight of Apatinib is 493.49 g/mol.
CAS No:
The CAS number of Apatinib is 811803-05-1.
Top ten keywords from Google and Synonyms:
Health benefits of this product:
Apatinib is primarily used for the treatment of various types of cancer, including gastric cancer, liver cancer, and non-small cell lung cancer. By inhibiting the signals that promote tumor growth and angiogenesis, Apatinib can slow or stop the progression of cancer and improve outcomes in patients with advanced or metastatic disease.
Potential effects:
Apatinib may have potential effects on the body and mind if not used properly. It can cause hypertension, proteinuria, and electrolyte imbalances, especially in patients with pre-existing cardiovascular or renal conditions. It can also interact with other medications and supplements, so it is important to disclose all medications and substances being used to healthcare providers.
Product mechanism:
Apatinib works by selectively inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in tumor growth and angiogenesis. The drug targets the VEGF signaling pathway, which plays a critical role in the development of new blood vessels that supply nutrients to tumors.
Safety:
Apatinib is generally considered safe when used as directed. However, caution should be exercised when taking the medication with other blood pressure medications or diuretics, as these combinations can increase the risk of hypertension and electrolyte imbalances. It can also cause fetal harm and should not be used during pregnancy.
Side effects:
The side effects of Apatinib include hypertension, fatigue, diarrhea, nausea, decreased appetite, and weight loss. In rare cases, it may cause more severe side effects such as arterial thromboembolic events, proteinuria, or liver damage. Patients with pre-existing cardiovascular or renal conditions should consult their healthcare provider before using Apatinib.
Dosing information:
The dosing of Apatinib varies depending on the indication and individual patient needs. When used for gastric cancer or liver cancer, the starting dose is typically 500 mg once daily, with adjustments made based on individual response. When used for non-small cell lung cancer, the recommended dose is 750 mg once daily.
Conclusion:
In summary, Apatinib is a tyrosine kinase inhibitor medication used primarily for the treatment of various types of cancer, including gastric cancer, liver cancer, and non-small cell lung cancer. The compound works by selectively inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in tumor growth and angiogenesis. While it can be effective in managing cancer and improving outcomes, caution must be exercised when using the medication due to its potential for interactions and rare but serious side effects. It is important to follow proper dosing and safety protocols when using Apatinib to prevent adverse health effects and optimize its therapeutic benefits
